Meeting
2017 ASCO Annual Meeting
Phase Ib study of tepotinib in EGFR-mutant/c-Met-positive NSCLC: Final data and long-term responders.
Authors
Yi-Long Wu
Guangdong Lung Cancer Institute, Guangdong General Hospital (GGH) and Guangdong Academy of Medical Sciences, Guangzhou, China
Yi-Long Wu , Ross A. Soo , Dong-Wan Kim , James Chih-Hsin Yang , Jürgen Scheele , Wenfeng Chen , Andreas Becker , Keunchil Park
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02864992
Citation
J Clin Oncol 35, 2017 (suppl; abstr 8547)
DOI
10.1200/JCO.2017.35.15_suppl.8547
Abstract #
8547
Poster Bd #
283
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Phase II two-arm study of tepotinib plus osimertinib in patients with EGFR-mutant NSCLC and acquired resistance to first-line osimertinib due to MET amplification: INSIGHT 2.
First Author: Viola Weijia Zhu
Poster
2017 ASCO Annual Meeting
Updated survival outcomes of NEJ005/TCOG0902, a randomized phase II study of concurrent (C) versus sequential alternating (S) gefitinib and chemotherapy in previously untreated non-small cell lung cancer (NSCLC) with sensitive epidermal growth factor receptor (EGFR) mutations.
First Author: Satoshi Oizumi
Poster
2017 ASCO Annual Meeting
Early TKI-pharmokinetics and circulating tumor DNA (ctDNA) to predict outcome in patients with EGFR-mutated non-small cell lung cancer (NSCLC).
First Author: Frederic Bigot
Poster
2016 ASCO Annual Meeting
Phase (Ph) II safety and efficacy results of a single-arm ph ib/II study of capmatinib (INC280) + gefitinib in patients (pts) with EGFR-mutated (mut), cMET-positive (cMET+) non-small cell lung cancer (NSCLC).
First Author: Yi-Long Wu